A new early-phase clinical trial suggests that Enolen, a novel implant designed to deliver the prostate cancer drug enzalutamide directly into tumors, is both safe and practical for patients with early-stage disease.
Researchers reported that no serious side effects above grade 3 were linked to either the implant procedure or the drug itself. Most patients experienced only mild issues such as temporary urinary retention or localized discomfort.
The treatment also showed encouraging early effectiveness. Nearly all 18 patients in the study experienced tumor shrinkage, including one patient whose tumor completely disappeared. The implant works by releasing the drug directly inside the prostate, avoiding widespread exposure throughout the body.
All patients were able to move forward with their planned prostate surgery, suggesting the treatment did not interfere with standard care. In January 2026, the U.S. Food and Drug Administration granted Enolen Fast Track designation for use in low- to intermediate-risk localized prostate cancer, highlighting its potential importance.
The study included patients with grade group 2 or higher disease. After MRI-guided implantation, surgery was performed weeks to months later, and additional groups of patients are now being enrolled to refine dosing and treatment duration.